Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Biogen Inc (BIIB) vs Bit Digital Inc (BTBT) Price & Performance

Biogen IncTrade
Bit Digital IncTrade

Price performance (Past 24H)

Key statistics

Biogen Inc vs Bit Digital Inc — how do they compare? Biogen Inc trades at $206.5 (market cap $30.13B), while Bit Digital Inc trades at $1.45 (market cap $471.05M). The key difference: Biogen Inc is far larger — about 64× Bit Digital Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Bit Digital Inc nearer its low. Which is the better fit depends on your goals.

BIIBBTBT
Market Cap
$30.13B$471.05M
Sector
HealthTechnology
52-Week High
$216.63$4.22
52-Week Low
$128.93$1.23
Enterprise Value
$37.20B$760.36M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Biogen Inc

Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.

The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.

Bit Digital Inc

BTBT trades at $1.485, up 14.23% in the last 24 hours, but remains in a bearish technical trend. The company reported a net loss of $80.32 million on $113.56 million revenue for 2025, with a negative net income margin of -145.45%. Recent earnings have missed expectations, though analyst consensus is a Buy with a $5.12 average price target.

The outlook is challenged by persistent losses and negative cash flow from operations, offset by strong financing activities. Key risks include execution on profitability and market volatility. The stock presents a high-risk opportunity contingent on the company's ability to reverse its negative earnings trend.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Read more on BIIB

About Bit Digital Inc

Bit Digital is a sustainability-focused digital asset production company. It primarily engages in Bitcoin mining and Ethereum staking while also providing high-performance computing (HPC) infrastructure for AI applications.

Read more on BTBT